300878 维康药业
已收盘 03-23 15:00:00
资讯
新帖
简况
维康药业新注册《中药提取自动化控制系统V1.0》项目的软件著作权
证券之星 · 03-19
维康药业新注册《中药提取自动化控制系统V1.0》项目的软件著作权
维康药业（300878）股东刘忠姣质押600万股，占总股本4.14%
证券之星 · 03-18
维康药业（300878）股东刘忠姣质押600万股，占总股本4.14%
维康药业最新公告：获得二冬汤颗粒药品注册证书
证券之星 · 01-26
维康药业最新公告：获得二冬汤颗粒药品注册证书
维康药业(300878.SZ)发预亏，预计2025年度归母净亏损1.7亿元至2.45亿元
智通财经 · 01-26
维康药业(300878.SZ)发预亏，预计2025年度归母净亏损1.7亿元至2.45亿元
异动快报：维康药业（300878）1月9日13点26分触及涨停板
证券之星 · 01-09
异动快报：维康药业（300878）1月9日13点26分触及涨停板
维康药业（300878）披露获得药品补充申请受理通知书，1月5日股价上涨11.56%
证券之星 · 01-05
维康药业（300878）披露获得药品补充申请受理通知书，1月5日股价上涨11.56%
维康药业（300878）披露部分募集资金专户注销公告，12月30日股价上涨0.08%
证券之星 · 2025-12-30
维康药业（300878）披露部分募集资金专户注销公告，12月30日股价上涨0.08%
维康药业（300878）披露公司药品生产许可证变更公告，12月15日股价下跌1.02%
证券之星 · 2025-12-15
维康药业（300878）披露公司药品生产许可证变更公告，12月15日股价下跌1.02%
维康药业（300878）披露拟变更会计师事务所公告，12月11日股价下跌3.26%
证券之星 · 2025-12-11
维康药业（300878）披露拟变更会计师事务所公告，12月11日股价下跌3.26%
维康药业陷多重困局：核心营销项目五年四度延期，上市后业绩断崖式暴跌至亏损
证券之星 · 2025-11-28
维康药业陷多重困局：核心营销项目五年四度延期，上市后业绩断崖式暴跌至亏损
维康药业：公司生产多种感冒流感相关药品
证券之星 · 2025-11-27
维康药业：公司生产多种感冒流感相关药品
维康药业（300878）披露拟变更会计师事务所公告，11月24日股价下跌2.48%
证券之星 · 2025-11-24
维康药业（300878）披露拟变更会计师事务所公告，11月24日股价下跌2.48%
维康药业（300878）2025年三季报简析：净利润同比下降380.87%，三费占比上升明显
证券之星 · 2025-10-31
维康药业（300878）2025年三季报简析：净利润同比下降380.87%，三费占比上升明显
图解维康药业三季报：第三季度单季净利润同比下降299.41%
证券之星 · 2025-10-29
图解维康药业三季报：第三季度单季净利润同比下降299.41%
维康药业(300878)9月30日股东户数1.06万户，较上期增加7.09%
证券之星 · 2025-10-29
维康药业(300878)9月30日股东户数1.06万户，较上期增加7.09%
维康药业：黄甲软肝颗粒项目处于Ⅲ期临床研究阶段
证券之星 · 2025-10-22
维康药业：黄甲软肝颗粒项目处于Ⅲ期临床研究阶段
维康药业：任绍忠、钟德颂等人因未依法履行其他职责被浙江证监局出具警示函
证券之星 · 2025-10-22
维康药业：任绍忠、钟德颂等人因未依法履行其他职责被浙江证监局出具警示函
维康药业连亏2年半 2020年上市募8.3亿国联民生保荐
中金财经 · 2025-10-09
维康药业连亏2年半 2020年上市募8.3亿国联民生保荐
维康药业(300878.SZ)：黄甲软肝颗粒启动临床三期试验
智通财经 · 2025-09-25
维康药业(300878.SZ)：黄甲软肝颗粒启动临床三期试验
维康药业最新公告：产品血塞通分散片中选全国中成药采购联盟集中带量采购
证券之星 · 2025-02-11
维康药业最新公告：产品血塞通分散片中选全国中成药采购联盟集中带量采购
加载更多
公司概况
公司名称：
浙江维康药业股份有限公司
所属行业：
医药制造业
上市日期：
2020-08-24
主营业务：
浙江维康药业股份有限公司的主营业务是现代中药及西药的研发、生产和销售。公司的主要产品是银黄滴丸、益母草软胶囊、益母草分散片、七叶神安分散片、枫蓼肠胃康分散片、人参健脾片、罗红霉素软胶囊。
发行价格：
41.34
{"stockData":{"symbol":"300878","market":"SZ","secType":"STK","nameCN":"维康药业","latestPrice":25.24,"timestamp":1774249413000,"preClose":26.94,"halted":0,"volume":1717400,"delay":0,"changeRate":-0.0631,"floatShares":144000000,"shares":145000000,"eps":-2.1782,"marketStatus":"已收盘","change":-1.7,"latestTime":"03-23 15:00:00","open":27.21,"high":27.21,"low":21.61,"amount":44334600,"amplitude":0.2079,"askPrice":25.25,"askSize":10,"bidPrice":25.24,"bidSize":69,"shortable":0,"etf":0,"ttmEps":-2.1782,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1774315800000},"marketStatusCode":5,"adr":0,"adjPreClose":26.94,"symbolType":"stock","openAndCloseTimeList":[[1774229400000,1774236600000],[1774242000000,1774249200000]],"highLimit":29.63,"lowLimit":24.25,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":144790322,"isCdr":false,"pbRate":3.85,"roa":"--","roe":"--","epsLYR":-1.03,"committee":0.187097,"marketValue":3655000000,"turnoverRate":0.0119,"status":1,"floatMarketCap":3638000000},"requestUrl":"/m/hq/s/300878","defaultTab":"news","newsList":[{"id":"2620266742","title":"维康药业新注册《中药提取自动化控制系统V1.0》项目的软件著作权","url":"https://stock-news.laohu8.com/highlight/detail?id=2620266742","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620266742?lang=zh_cn&edition=full","pubTime":"2026-03-19 02:16","pubTimestamp":1773857774,"startTime":"0","endTime":"0","summary":"证券之星消息，近日维康药业（300878）新注册了《中药提取自动化控制系统V1.0》项目的软件著作权。今年以来维康药业新注册软件著作权1个。结合公司2025年中报财务数据，2025上半年公司在研发方面投入了599.58万元，同比减8.88%。通过天眼查大数据分析，浙江维康药业股份有限公司共对外投资了7家企业，参与招投标项目6658次；财产线索方面有商标信息152条，专利信息140条，著作权信息2条；此外企业还拥有行政许可460个。数据来源：天眼查APP以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031900001167.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300878","BK0239"],"gpt_icon":0},{"id":"2620234260","title":"维康药业（300878）股东刘忠姣质押600万股，占总股本4.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2620234260","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620234260?lang=zh_cn&edition=full","pubTime":"2026-03-18 18:22","pubTimestamp":1773829348,"startTime":"0","endTime":"0","summary":"证券之星消息，维康药业3月18日公开信息显示，股东刘忠姣向深圳市佳银典当有限公司合计质押600.0万股，占总股本4.14%。质押详情见下表：截止本公告日，股东刘忠良已累计质押股份3100.0万股，占其持股总数的35.16%，股东刘忠姣已累计质押股份600.0万股，占其持股总数的60.78%。维康药业主营业务：现代中药及西药的研发、生产和销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031800033279.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300878"],"gpt_icon":0},{"id":"2606215696","title":"维康药业最新公告：获得二冬汤颗粒药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2606215696","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606215696?lang=zh_cn&edition=full","pubTime":"2026-01-26 17:24","pubTimestamp":1769419487,"startTime":"0","endTime":"0","summary":"维康药业(300878.SZ)公告称，公司近日收到国家药品监督管理局核准签发的《药品注册证书》，药品名称为二冬汤颗粒，剂型为颗粒剂，规格为每袋相当于饮片12.44g。该药品的获批进一步丰富了公司的产品线，有助于提升公司产品的市场竞争力。然而，医药产品具有高科技、高风险、高附加值的特点，药品获得批件后，产品销售易受到行业政策变动、招标采购、市场环境变化等因素影响，存在不确定性。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012600022880.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300878"],"gpt_icon":0},{"id":"2606109297","title":"维康药业(300878.SZ)发预亏，预计2025年度归母净亏损1.7亿元至2.45亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2606109297","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606109297?lang=zh_cn&edition=full","pubTime":"2026-01-26 15:57","pubTimestamp":1769414227,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维康药业(300878.SZ)披露2025年度业绩预告，公司预计归属于上市公司股东的净亏损1.7亿元至2.45亿元;扣除非经常性损益后的净亏损1.7亿元至2.45亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1397275.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","300878"],"gpt_icon":0},{"id":"2602341555","title":"异动快报：维康药业（300878）1月9日13点26分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2602341555","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602341555?lang=zh_cn&edition=full","pubTime":"2026-01-09 13:30","pubTimestamp":1767936650,"startTime":"0","endTime":"0","summary":"证券之星1月9日盘中消息，13点26分维康药业触及涨停板。其所属行业中药目前上涨。该股为肝炎概念，创新药，医药商业概念热股，当日肝炎概念概念上涨1.6%，创新药概念上涨1.33%，医药商业概念上涨1.1%。1月8日的资金流向数据方面，主力资金净流出667.62万元，占总成交额5.05%，游资资金净流入673.11万元，占总成交额5.09%，散户资金净流出5.49万元，占总成交额0.04%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010900018369.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300878"],"gpt_icon":0},{"id":"2601000929","title":"维康药业（300878）披露获得药品补充申请受理通知书，1月5日股价上涨11.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601000929","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601000929?lang=zh_cn&edition=full","pubTime":"2026-01-05 18:16","pubTimestamp":1767608176,"startTime":"0","endTime":"0","summary":"截至2026年1月5日收盘，维康药业报收于28.46元，较前一交易日上涨11.56%，最新总市值为41.21亿元。公司近日发布公告称，浙江维康药业股份有限公司近日获得国家药品监督管理局出具的金钱草胶囊补充申请《受理通知书》，受理号为CYZB2503241。该申请事项为境内生产药品补充申请。截至目前，国内已有四川省通园制药集团有限公司、江西博士达药业有限责任公司取得该品种药品批准文号。本次补充申请获受理对公司近期业绩无影响，后续是否获批存在不确定性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010500028194.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300878","BK0239"],"gpt_icon":0},{"id":"2595795617","title":"维康药业（300878）披露部分募集资金专户注销公告，12月30日股价上涨0.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595795617","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595795617?lang=zh_cn&edition=full","pubTime":"2025-12-30 17:57","pubTimestamp":1767088646,"startTime":"0","endTime":"0","summary":"截至2025年12月30日收盘，维康药业报收于25.77元，较前一交易日上涨0.08%，最新总市值为37.31亿元。该股当日开盘25.74元，最高26.56元，最低25.5元，成交额达7448.17万元，换手率为1.98%。近日，维康药业发布公告称，因首次公开发行股票募投项目“医药大健康产业园一期项目”已结项，经董事会及股东大会审议通过，公司将节余募集资金永久补充流动资金，并注销中国工商银行丽水经济开发区支行的募集资金专户。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123000030840.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300878","BK0239"],"gpt_icon":0},{"id":"2591647539","title":"维康药业（300878）披露公司药品生产许可证变更公告，12月15日股价下跌1.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2591647539","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591647539?lang=zh_cn&edition=full","pubTime":"2025-12-15 22:39","pubTimestamp":1765809570,"startTime":"0","endTime":"0","summary":"截至2025年12月15日收盘，维康药业报收于21.26元，较前一交易日下跌1.02%，最新总市值为30.78亿元。该股当日开盘21.54元，最高21.73元，最低21.15元，成交额达4388.96万元，换手率为1.42%。公司近日发布公告称，浙江维康药业股份有限公司近日取得浙江省药品监督管理局换发的《药品生产许可证》，有效期至2030年12月11日。本次换发系因原许可证到期，新证的取得确保公司正常生产经营，对公司业绩无重大影响。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121500036365.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300878"],"gpt_icon":0},{"id":"2590594420","title":"维康药业（300878）披露拟变更会计师事务所公告，12月11日股价下跌3.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590594420","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590594420?lang=zh_cn&edition=full","pubTime":"2025-12-11 18:02","pubTimestamp":1765447320,"startTime":"0","endTime":"0","summary":"截至2025年12月11日收盘，维康药业报收于21.66元，较前一交易日下跌3.26%，最新总市值为31.36亿元。该股当日开盘22.38元，最高22.47元，最低21.66元，成交额达5869.14万元，换手率为1.85%。根据公司近日发布的公告，浙江维康药业股份有限公司于2025年12月10日召开2025年第一次临时股东大会，审议通过了《关于拟变更会计师事务所的议案》。浙江天册律师事务所对本次股东大会出具了法律意见书，确认会议表决程序合法合规，表决结果合法有效。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121100029916.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300878","BK0239"],"gpt_icon":0},{"id":"2586888807","title":"维康药业陷多重困局：核心营销项目五年四度延期，上市后业绩断崖式暴跌至亏损","url":"https://stock-news.laohu8.com/highlight/detail?id=2586888807","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586888807?lang=zh_cn&edition=full","pubTime":"2025-11-28 17:25","pubTimestamp":1764321943,"startTime":"0","endTime":"0","summary":"时至今日，维康药业的这一项目未能落地。2025年8月，维康药业称，公司拟将“营销网络中心建设项目”达到预定可使用状态的日期由2025年6月30日延长至2026年6月30日。维康药业上市之后业绩出现变脸，尤其是归母净利润呈“断崖式”下滑趋势，并在2023年首次亏损。维康药业称，营收下滑主要系本期合并范围减少所致。依据相关规定，浙江证监局决定对维康药业及公司多名责任人给予警告并处罚款，罚款金额总计1460万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2025112800025305.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300878","BK0239"],"gpt_icon":0},{"id":"2586240405","title":"维康药业：公司生产多种感冒流感相关药品","url":"https://stock-news.laohu8.com/highlight/detail?id=2586240405","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586240405?lang=zh_cn&edition=full","pubTime":"2025-11-27 20:51","pubTimestamp":1764247903,"startTime":"0","endTime":"0","summary":"证券之星消息，维康药业11月26日在投资者关系平台上答复投资者关心的问题。上述产品具体使用方法请遵医嘱或根据产品说明书使用。感谢您对公司的关注，谢谢！","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112700035545.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300878"],"gpt_icon":0},{"id":"2585498744","title":"维康药业（300878）披露拟变更会计师事务所公告，11月24日股价下跌2.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2585498744","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585498744?lang=zh_cn&edition=full","pubTime":"2025-11-24 22:40","pubTimestamp":1763995215,"startTime":"0","endTime":"0","summary":"截至2025年11月24日收盘，维康药业报收于27.48元，较前一交易日下跌2.48%，最新总市值为39.79亿元。该股当日开盘27.62元，最高28.5元，最低27.22元，成交额达9623.63万元，换手率为2.42%。其中，拟变更会计师事务所事项受到市场关注。本次股东大会采取现场表决与网络投票相结合的方式进行，股权登记日为2025年12月3日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112400036371.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300878","BK0239"],"gpt_icon":0},{"id":"2579101440","title":"维康药业（300878）2025年三季报简析：净利润同比下降380.87%，三费占比上升明显","url":"https://stock-news.laohu8.com/highlight/detail?id=2579101440","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579101440?lang=zh_cn&edition=full","pubTime":"2025-10-31 06:54","pubTimestamp":1761864859,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期维康药业发布2025年三季报。截至本报告期末，公司营业总收入1.51亿元，同比下降59.2%，归母净利润-1.24亿元，同比下降380.87%。按单季度数据看，第三季度营业总收入3674.79万元，同比下降50.25%，第三季度归母净利润-5963.49万元，同比下降299.41%。本报告期维康药业三费占比上升明显，财务费用、销售费用和管理费用总和占总营收同比增幅达35.87%。本次财报公布的各项数据指标表现不尽如人意。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103100010225.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300878"],"gpt_icon":0},{"id":"2579972126","title":"图解维康药业三季报：第三季度单季净利润同比下降299.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579972126","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579972126?lang=zh_cn&edition=full","pubTime":"2025-10-29 19:11","pubTimestamp":1761736269,"startTime":"0","endTime":"0","summary":"证券之星消息，维康药业2025年三季报显示，前三季度公司主营收入1.51亿元，同比下降59.2%；归母净利润-1.24亿元，同比下降380.87%；扣非净利润-1.22亿元，同比下降157.75%；其中2025年第三季度，公司单季度主营收入3674.79万元，同比下降50.25%；单季度归母净利润-5963.49万元，同比下降299.41%；单季度扣非净利润-5736.26万元，同比下降2.75%；负债率30.8%，财务费用462.77万元，毛利率15.34%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102900040023.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300878"],"gpt_icon":0},{"id":"2579978730","title":"维康药业(300878)9月30日股东户数1.06万户，较上期增加7.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579978730","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579978730?lang=zh_cn&edition=full","pubTime":"2025-10-29 17:37","pubTimestamp":1761730660,"startTime":"0","endTime":"0","summary":"证券之星消息，近日维康药业披露，截至2025年9月30日公司股东户数为1.06万户，较6月30日增加701.0户，增幅为7.09%。在中药行业个股中，维康药业股东户数低于行业平均水平，截至9月30日，中药行业平均股东户数为5.34万户。从股价来看，2025年6月30日至2025年9月30日，维康药业区间涨幅为39.1%，在此期间股东户数增加701.0户，增幅为7.09%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102900036676.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300878","BK0239"],"gpt_icon":0},{"id":"2577362492","title":"维康药业：黄甲软肝颗粒项目处于Ⅲ期临床研究阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2577362492","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577362492?lang=zh_cn&edition=full","pubTime":"2025-10-22 20:51","pubTimestamp":1761137483,"startTime":"0","endTime":"0","summary":"证券之星消息，维康药业(300878)10月21日在投资者关系平台上答复投资者关心的问题。投资者提问：你好：黄甲软肝颗粒大概什么时候可以上市维康药业回复：尊敬的投资者，您好！黄甲软肝颗粒项目处于Ⅲ期临床研究阶段，后续公司会在定期报告中详细说明主要研发项目及其研发进展情况，另外如有相关需披露事项公司会按照规定及时披露，敬请持续关注公司公告。感谢您对公司的关注，谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102200036005.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300878","BK0239"],"gpt_icon":0},{"id":"2577236583","title":"维康药业：任绍忠、钟德颂等人因未依法履行其他职责被浙江证监局出具警示函","url":"https://stock-news.laohu8.com/highlight/detail?id=2577236583","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577236583?lang=zh_cn&edition=full","pubTime":"2025-10-22 19:00","pubTimestamp":1761130859,"startTime":"0","endTime":"0","summary":"证券之星消息，10月21日维康药业公开信息显示，民生证券股份有限公司，任绍忠、钟德颂因未依法履行其他职责被浙江证监局出具警示函。二是在出具维康药业2023年度持续督导文件过程中,核查结论不够谨慎,投行业务内部控制存在缺陷。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102200031490.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300878"],"gpt_icon":0},{"id":"2574855851","title":"维康药业连亏2年半 2020年上市募8.3亿国联民生保荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2574855851","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574855851?lang=zh_cn&edition=full","pubTime":"2025-10-09 10:52","pubTimestamp":1759978326,"startTime":"0","endTime":"0","summary":"中国经济网北京10月9日讯 维康药业 日前披露2025年半年度报告。 2025年1-6月，公司实现营业收入1.15亿元，同比下降61.42%；归属于上市公司股东的净利润为-6,421.97万元，上年同期为1,419.21万元；归属于上市公司股东的扣除非经常性损益的净利润为-6,482.63万元，上年同期为842.31万元；经营活动产生的现金流量净额为4,440.51万元，同比增长323.28%。 维康药业于上市次日即2020年8月25日创下截至目前的股价最高点109.80元。","market":"fut","thumbnail":" http://caiji.3g.cnfol.com/colect/202510/09/20251009867965.png","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202510/09/20251009867965.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20251009/31691847.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["01456","BK1147","BK0239","300878","BK1564","BK0276","601456"],"gpt_icon":0},{"id":"2570060707","title":"维康药业(300878.SZ)：黄甲软肝颗粒启动临床三期试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2570060707","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570060707?lang=zh_cn&edition=full","pubTime":"2025-09-25 17:38","pubTimestamp":1758793091,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维康药业 公告，公司与盈科瑞制药有限公司共同申办，牵头单位为上海中医药大学附属曙光医院和参研的安徽医科大学第一附属医院、重庆大学附属三峡医院、重庆医科大学附属第一医院等19家临床试验中心组织召开了关于开展“评价黄甲软肝颗粒治疗慢性乙型病毒性肝炎肝纤维化的有效性和安全性的随机、双盲、多中心、安慰剂对照的Ⅲ期临床试验”的项目启动会。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1349398.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300878","BK0239"],"gpt_icon":0},{"id":"2510802265","title":"维康药业最新公告：产品血塞通分散片中选全国中成药采购联盟集中带量采购","url":"https://stock-news.laohu8.com/highlight/detail?id=2510802265","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510802265?lang=zh_cn&edition=full","pubTime":"2025-02-11 19:29","pubTimestamp":1739273393,"startTime":"0","endTime":"0","summary":"维康药业公告称，公司产品血塞通分散片中选全国中成药采购联盟集中带量采购（首批扩围接续）。血塞通分散片在2024年的销售额约为2600万元，其中每盒40片规格的销售额约为480万元。采购周期内，医疗机构将优先使用中选药品，这将有利于扩大产品销售规模，提高市场占有率，对公司未来经营业绩有积极影响。但血塞通分散片的采购协议签订等后续事项及影响程度尚不确定。以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025021100033213.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300878"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1774259370083,"stockEarnings":[{"period":"1week","weight":-0.0865},{"period":"1month","weight":-0.0707},{"period":"3month","weight":0.1234},{"period":"6month","weight":0.1319},{"period":"1year","weight":0.6931},{"period":"ytd","weight":0.0561}],"compareEarnings":[{"period":"1week","weight":-0.0338},{"period":"1month","weight":-0.0306},{"period":"3month","weight":0.0171},{"period":"6month","weight":0.0359},{"period":"1year","weight":0.1608},{"period":"ytd","weight":-0.003}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"浙江维康药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"10593人(较上一季度增加7.09%)","perCapita":"13605股","listingDate":"2020-08-24","address":"浙江省丽水市莲都区经济开发区遂松路2号","registeredCapital":"14479万元","survey":" 浙江维康药业股份有限公司的主营业务是现代中药及西药的研发、生产和销售。公司的主要产品是银黄滴丸、益母草软胶囊、益母草分散片、七叶神安分散片、枫蓼肠胃康分散片、人参健脾片、罗红霉素软胶囊。","listedPrice":41.34},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.37.0","shortVersion":"4.37.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"维康药业(300878)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供维康药业(300878)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"维康药业,300878,维康药业股票,维康药业股票老虎,维康药业股票老虎国际,维康药业行情,维康药业股票行情,维康药业股价,维康药业股市,维康药业股票价格,维康药业股票交易,维康药业股票购买,维康药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"维康药业(300878)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供维康药业(300878)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}